Skip to main content

Advertisement

SpringerLink
Log in

Increased expression of p53 and p21 (Waf1/Cip1) in the lesional skin of bleomycin-induced scleroderma

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Systemic sclerosis (SSc) is a connective tissue disorder characterized by excessive deposition of extracellular matrix in the affected skin as well as various internal organs, vascular injury and immune abnormality; however, the etiology of SSc remains still unknown. We previously established an experimental mouse model for scleroderma by repeated local injections of bleomycin, a DNA damaging agent. In this study, we examined the induction of apoptosis and the expression of p53, p21 (Waf1/Cip1), and proliferating cell nuclear antigen (PCNA) in the lesional skin following bleomycin exposure in this model. Dermal sclerosis was induced by alternate day’s injections of bleomycin for 4 weeks. TUNEL assay showed that apoptotic cells began to appear at 1 week after bleomycin exposure, and were prominently detected at 3–4 weeks. Immunohistochemical examination showed increased expression of p53 and p21 mainly in the infiltrating mononuclear cells at 2 weeks after bleomycin treatment. Bleomycin treatment markedly enhanced PCNA expression at 1–2 weeks, mainly in mesenchyme, as compared with control phosphate buffered saline treatment. Reverse transcriptase-polymerase chain reaction analysis showed that the expression of p53 and p21 mRNA was concurrently upregulated at 1–2 weeks after bleomycin treatment. Taken together, coordinate increased levels of p53 and p21 preceded the maximal induction of apoptosis and dermal sclerosis. Our findings suggest that apoptotic processes are involved in the pathophysiology of bleomycin-induced scleroderma, which may be mediated, in part, by the upregulation of p53 and p21.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Krieg T, Meurer M (1988) Systemic scleroderma. Clinical and pathophysiological aspects. J Am Acad Dermatol 18:457–481

    Google Scholar 

  2. LeRoy EC, Trojanowska M, Smith EA (1991) The pathogenesis of scleroderma (systemic sclerosis, SSc). Clin Exp Rheumatol 9:173–177

    Google Scholar 

  3. Bostein GR, Sherer GK, LeRoy EC (1982) Fibroblast selection in scleroderma. An alternative model of fibrosis. Arthritis Rheum 25:189–195

    Google Scholar 

  4. Krieg T, Perlish JS, Fleischmajer R, Timpl R (1986) Collagen synthesis by scleroderma fibroblasts. Ann NY Acad Sci 460:375–378

    Google Scholar 

  5. Mauch C, Eckes B, Hunzelmann N, Oono T, Kozlowska E, Krieg T (1993) Control of fibrosis in systemic scleroderma. J Invest Dermatol 100:92–96

    Google Scholar 

  6. Aso Y, Yoneda K, Kikkawa Y (1976) Morphological and biological study of pulmonary changes induced by bleomycin in mice. Lab Invest 35:558–568

    Google Scholar 

  7. Thrall RS, McCormick JR, Jack RM, McReynolds RA, Ward PA (1979) Bleomycin-induced pulmonary fibrosis in the rat: inhibition with indomethacin. Am J Pathol 95:117–127

    Google Scholar 

  8. Chandler DB, Hyde DM, Giri SN (1983) Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am J Pathol 112:170–177

    Google Scholar 

  9. Bowden DH (1984) Unraveling pulmonary fibrosis: the bleomycin model. Lab Invest 50:487–488

    Google Scholar 

  10. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311

    CAS  PubMed  Google Scholar 

  11. Lane DP (1992) p53, guardian of the genome. Nature 358:15–16

    Article  CAS  PubMed  Google Scholar 

  12. Lane DP (1993) A death in the life of p53. Nature 362:786–787

    Google Scholar 

  13. Lotem J, Peled-Kamar M, Groner Y, Sachs L (1996) Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and the cytokines. Proc Natl Acad Sci USA 93:9166–9171

    Google Scholar 

  14. Harper J, Adami G, Wei N, Keyomarsi K, Elledge S (1993) The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816

    Article  CAS  PubMed  Google Scholar 

  15. El-Deiry W, Tokino T, Velculescu V, Levy D, Parsons R, Trent J, Lin D, Mercer W, Kinzler K, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825

    Google Scholar 

  16. Waga S, Hannon G, Beach D, Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574–578

    Google Scholar 

  17. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K (1999) Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112:456–462

    Google Scholar 

  18. Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K (1999) Animal model of sclerotic skin. II: Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/WV mice. J Rheumatol 26:2628–2634

    Google Scholar 

  19. Yamamoto T, Kuroda M, Takagawa S, Nishioka K (2000) Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 292:535–541

    Google Scholar 

  20. Yamamoto T, Nishioka K (2001) Animal model of sclerotic skin. IV: Induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 117:999–1001

    Google Scholar 

  21. Yamamoto T, Nishioka K (2002) Animal model of sclerotic skin. V: Increased expression of α-smooth muscle actin in fibroblastic cells in the lesional skin of bleomycin-induced scleroderma. Clin Immunol 102:77–83

    Google Scholar 

  22. Amundson SA, Myers TG, Fornace AJ Jr (1998) Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 25:3287–3299

    Google Scholar 

  23. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299

    CAS  PubMed  Google Scholar 

  24. Kuerbitz S, Plunkett B, Walsh W, Kastan M (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491–7495

    CAS  PubMed  Google Scholar 

  25. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331

    Article  CAS  PubMed  Google Scholar 

  26. Sfikakis PP, Gorgoulis VG, Kapsogeorgou EK, Tsoli E, Manoussakis MN (2002) Absence of p53 gene mutations in skin fibroblasts derived from patients with systemic sclerosis. Eur J Clin Invest 32:139–140

    Google Scholar 

  27. Oberosler P, Hloch P, Ramsperger U, Stahl H (1993) p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J 12:2389–2396

    Google Scholar 

  28. Morris GF, Bischoff JR, Mathews MB (1996) Transcriptional activation of the human proliferating cell nuclear antigen promoter by p53. Proc Natl Acad Sci USA 93:895–899

    Google Scholar 

  29. Shivakumar CV, Brown DR, Deb S, Deb SP (1995) Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 15:6785–6793

    Google Scholar 

  30. Bravo R, Frank R, Blundell P, Macdonald-Bravo H (1987) Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 326:515–517

    Google Scholar 

  31. Michieli PM, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391–3395

    Google Scholar 

  32. Li CY, Suardet L, Little JB (1995) Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J Biol Chem 270:4971–4974

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Tokyo Medical and Dental University, School of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

    Toshiyuki Yamamoto & Kiyoshi Nishioka

Authors
  1. Toshiyuki Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kiyoshi Nishioka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiyuki Yamamoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, T., Nishioka, K. Increased expression of p53 and p21 (Waf1/Cip1) in the lesional skin of bleomycin-induced scleroderma. Arch Dermatol Res 296, 509–513 (2005). https://doi.org/10.1007/s00403-005-0550-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-005-0550-3

Keywords

Search

Navigation